Do You Have a Position in Zimmer Biomet? Here's the Essential Facts.

Large-cap Health Care company Zimmer Biomet has logged a 1.5% change today on a trading volume of 193,154. The average volume for the stock is 1,515,996.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Based in Warsaw, United States the company has 18,000 full time employees and a market cap of $25,598,089,216. Zimmer Biomet currently offers its equity investors a dividend that yields 0.8% per year.

The company is now trading -18.41% away from its average analyst target price of $150.15 per share. The 23 analysts following the stock have set target prices ranging from $120.0 to $172.0, and on average give Zimmer Biomet a rating of hold.

Over the last 52 weeks, ZBH stock has risen 3.0%, which amounts to a -7.0% difference compared to the S&P 500. The stock's 52 week high is $149.25 whereas its 52 week low is $102.6 per share. With its net margins declining an average -27.5% over the last 6 years, Zimmer Biomet may not have a strong enough profitability trend to support its stock price.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023-02-24 6,939,900 231,400 3 -50.0
2022-02-25 6,827,300 401,600 6 400.0
2021-02-22 6,127,500 -138,900 -2 -114.29
2020-02-21 7,982,200 1,131,600 14 380.0
2019-02-26 7,932,900 -379,200 -5 -121.74
2018-02-27 7,803,300 1,813,800 23
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.